TP53 and cancer: Collectively, these data demonstrate that under complete or partial genetic Cox-2 ablation, ZD stimulated RAGE-S100A8 inflammatory signaling cancer-and p53-associated response pathways, thereby driving malignant tumor progression and bypassing the antitumor effect of COX-2 blockade.